Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/16/2024 | $5.00 | Neutral → Buy | Ladenburg Thalmann |
1/31/2023 | $8.00 | Buy | Jefferies |
1/27/2023 | $9.00 | Buy | Stifel |
5/23/2022 | $12.00 | Buy | H.C. Wainwright |
3/15/2022 | $7.00 | Buy | Ladenburg Thalmann |
1/19/2022 | $10.00 | Buy | B. Riley Securities |
12/22/2021 | $5.00 | Outperform | Raymond James |
12/20/2021 | $12.00 | Outperform | SVB Leerink |
New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.Predictive biomarkers correlated with response and changes in pharmacodynamic markers were seen in patients treated with CTX-471, a novel anti-CD137 agonist antibody, in an analysis from the Phase 1 monotherapy study. BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled "Pharmacodynamic and Response Biomarkers in t
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the acceptance of an abstract for poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Poster Title: Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody Authors: Kris Sachsenmeier, Niharika Mettu, Marti
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2024. Details are as follows: H.C. Wainwright 26th Annual Global Investment Conference Location: New York, NY Date: Monday, September 9, 2024 Time: 11:00am ETWebcast Link: https://journey.ct.events/ Cantor Global Healthcare Conference Location: New York, NYDate: Tuesday, September 17, 2024Time: 8:35am ET Webcast Link: https://wsw.com/webcast/cantor
Gainers Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. The market value of their outstanding shares is at $7.1 million. Akanda (NASDAQ:AKAN) stock rose 7.74% to $2.92. The company's market cap stands at $5.5 million. LifeMD (NASDAQ:LFMD) stock rose 5.81% to $8.0. The market value of their outstanding shares is at $327.0 million. Purple Biotech (NASDAQ:PPBT) shares rose 5.79% to $0.58. The company's market cap stands at $15.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 5.29% to $0.44. The market value of their outstanding shares is at $2.0 million. Compass Therapeutics (NASDAQ:CMPX) shares increased by 4.95% to $1.27. The
HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 price target.
Bisker-Leib will continue to be available to the Company as a Senior Consultant for the next 15 months.
Ladenburg Thalmann upgraded Compass Therapeutics from Neutral to Buy and set a new price target of $5.00
Jefferies initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $8.00
Stifel initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $9.00
SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
3 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC). Initial data expected in the third quarter of 2023Presented results of a Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers SymposiumExpanded the management team with the appointment of Minori Rosales, M.D. PhD, as Senior Vice President & Head of Clinical DevelopmentAppointed Richard Lindahl, M.B.A., EVP & CFO of Emergent BioSolutio
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administration (FDA) has granted Entera's request for a Type C Meeting based on the revised phase 3 registrational study for lead clinical asset, EB613 (oral formulation of PTH (1-34, teriparatide), as the first oral anabolic drug to treat post-menopausal women with osteoporosis. The meeting is expected in H2 2022Following its End of Phase 2 Meeting with the FDA, Entera designed the pivotal study for EB613 as an 18 month double blind placebo-contro
EFFECT - Compass Therapeutics, Inc. (0001738021) (Filer)
S-3 - Compass Therapeutics, Inc. (0001738021) (Filer)
10-Q - Compass Therapeutics, Inc. (0001738021) (Filer)
Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion. Webinar Details: Date: May 04, 2022 Time: 8:00 a.m. ET Webcast: Registration Link Replay availability: A replay will be available on the Compass website for 6 months. Abo
NEW YORK, July 20, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter 2021 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index. The OTCQX Composite Index (.OTCQX), a benchmark for the overall OTCQX Best Market, was up 3.9% in the second quarter. Ninety-two new companies were added to the index, including: AirBoss of America Corp. (OTCQX:ABSSF); Blackrock Silver Corp. (OTCQX:BKRRF); Belo Sun Mining Corp. (OTCQX:BSXGF); Caldwell Partners International Inc. (OTCQX:CWLPF); Graphite One Inc. (OTCQX:GPHOF)